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AbstrACt
Objective To assess the methodological advantages and 
disadvantages of parallel and crossover designs in randomised 
clinical trials on methylphenidate for children and adolescents 
with attention deficit hyperactivity disorder (ADHD).
Design Secondary analyses of a Cochrane systematic review.
setting and participants We searched relevant databases 
up to March 2015 and included data from parallel and 
crossover randomised trials assessing children and 
adolescents up to 18 years with ADHD.
Interventions Methylphenidate compared with placebo or 
no-treatment interventions.
Primary and secondary outcomes The primary outcomes 
were teacher-rated ADHD symptoms and serious adverse 
events. The secondary outcomes were non-serious adverse 
events.
results We included 38 parallel trials (n=5111) and 147 
crossover trials (n=7134). When comparing methylphenidate 
with placebo or no-treatment on ADHD symptoms, we found 
no differences between the end of parallel trials and the 
first-period from crossover trials (Χ²=1.06, df=1, p=0.30, 
I²=5.5%). We also found no differences when combining the 
end of first-period crossover trials with the end of parallel 
trials and comparing them to the end of last-period crossover 
trials (Χ²=3.25, df=1, p=0.07, I²=69.2%). We found no 
differences in serious and non-serious adverse events, and no 
risk of period and carryover effects. However, only two trials 
contributed data to the latter analyses.
Conclusions Both parallel and crossover trials seem suitable 
for investigating methylphenidate in children and adolescents 
with ADHD, with comparable estimates on ADHD symptom 
severity and adverse events. However, parallel trials might still 
offer ethical and statistical advantages over crossover trials.
IntrODuCtIOn   
Attention deficit-hyperactivity disorder 
(ADHD), one of the most common mental 
disorders among children and adoles-
cents, is characterised by inattention, 
hyperactivity and impulsivity.1 2 The first-
choice pharmaceutical treatment for ADHD 
is methylphenidate,3 a central nervous system 
stimulant exerting agonistic effects on dopa-
mine and norepinephrine in the brain-stem 
and neocortex.4 We previously conducted a 
Cochrane systematic review on methylphe-
nidate for children and adolescents with 
ADHD and found significant improvements 
on ADHD symptoms, general behaviour and 
quality of life, but the included randomised 
clinical trials (RCTs) suffered from low to 
very low evidence certainty.5 
Crossover designs were about four times 
more frequent than parallel designs in the 
review.5 Clinical trials with crossover designs 
allocate participants to different interventions 
strengths and limitations of this study
 ► Study strengths include publishing a protocol in 
accordance with The Cochrane Collaboration guide-
lines, conducting a broad and comprehensive lit-
erature search, and assessing both published and 
unpublished data.
 ► The Food and Drug Administration and European 
Medicine Agency databases were not searched for 
unpublished data.
 ► The analysis comparing the end of first-period and 
last-period crossover trials included two trials only 
and might suffer from low power and spurious data.
 ► Methylphenidate gives rise to several easily recog-
nisable adverse events, which may lead to loss of 
blinding and influence symptom ratings.
 ► A total of 179 trials (97%) were considered at high 
risk of bias, leading to decreased confidence in the 
effect estimates.
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over two or more time periods, whereas in parallel trials, 
participants are randomised to the same intervention over 
a single period of time.6 Crossover trials may offer more 
precise estimates of intervention effects compared with 
a parallel trial because they would remove any biological 
and methodological variation. Hence, less participants 
need to be randomised to observe intervention effects.7 
Importantly, the first period of a crossover trial can be 
viewed as independent and identical to a parallel trial.7–9 
Crossover trials typically last longer (which may inflate 
attrition rates) and involve fewer participants than parallel 
trials.7 8 10 However, since the participants are allocated to 
different interventions over time, it makes it potentially 
challenging to determine the causality.11 Moreover, the 
crossover design is only suitable for a condition that is 
stable, when intervention effects are short-lived, and do 
not cure the condition.7 Parallel trials are versatile, simple 
and easy to incorporate into meta-analyses compared with 
crossover trials, but they usually require larger sample 
sizes.7 12
The optimal way to incorporate data from crossover 
trials into meta-analyses is to retrieve data from all time 
periods,13 14 but such data are often unavailable. Another 
option is to impute missing data and adjust for ‘unit of 
analysis errors’ by conducting covariate analyses (for 
continuous data) or adjust for the variance to account 
for the correlation coefficient (dichotomous data).6 13 14 
A third option is to ignore the crossover design, and treat 
all time periods as parallel designs. However, this intro-
duces the possibility for ‘unit of analysis errors’ as the 
same patients receive both interventions.15 The data are 
therefore not independent, which is typically required for 
standard statistical methods.13
Crossover trials may also be biased by carryover and 
period effects. Carryover effects occur when an interven-
tion effect during one time period is carried over and 
interferes with a subsequent period.6 7 9 12 14 This can be 
controlled for by introducing washout periods between 
intervention periods, causing the effects of the initial 
intervention to dissipate.9 16 17 Period effects occur when 
treatment effects differ between time periods in cross-
over trials,16 17 but because randomisation procedures 
are thought to diminish period effects, they are usually 
not as serious as carryover effects.7 17 Carryover effects are 
generally less suspected in crossover trials on methylphe-
nidate because of its short pharmacokinetic half-life of 
1.5 to 3 hours, depending on the drug formulation.18–21 
However, poor reporting of carryover and period effects 
and the lack of rationale for using crossover designs, is 
widespread and problematic.10 14 17 22 
The aim of this study is to investigate the advan-
tages and disadvantages of parallel and crossover trials 
on methylphenidate for ADHD, and to assess the risk 
of carryover and period effects when using crossover 
designs. The study rationale was to determine whether 
crossover trials are suitable for assessing the benefits and 
harms of methylphenidate for ADHD relative to parallel 
trials, and whether authors in the field should be more 
cognisant of potential differences between the two trial 
designs.
MethODs
Data source
The data was derived from our Cochrane systematic 
review on the efficacy and adverse events of methylphe-
nidate in children and adolescents with ADHD.5 The 
methods and design adhered to The Cochrane Collabo-
ration standards for systematic review production.23 The 
protocol was published in The Cochrane Library.24
Patient involvement
No patients were involved in conducting this study.
study selection
We included parallel and crossover RCTs on methylphe-
nidate for children and adolescents with ADHD. Meth-
ylphenidate compared with placebo or no-treatment 
were to be administered regardless of dose and medical 
treatment regimen. We allowed co-interventions if the 
comparison groups received them simultaneously. All 
trials were included irrespective of language, publication 
type and publication status.
Inclusion criteria
We included children and adolescents, aged 18 or less, 
with a formal diagnosis of ADHD according to the 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM-III, DSM-III-R and DSM-IV, DSM-V)1 25–28 or the 
International Classification of Diseases (ICD-9, ICD-10).2 
The participants were included regardless of comorbid 
conditions. At least 75% were required to have normal 
intellectual capacity (IQ>70), and 75% had to be under 
18 years of age, with a mean of 18 or less.
We contacted authors of crossover trials to obtain data 
for all time periods if the trial report lacked informa-
tion. We assessed study quality and risk of bias according 
to Grades of Recommendation, Assessment, Develop-
ment and Evaluation standards and the Cochrane guide-
lines.5 23 29 For risk of bias, each study was assigned one of 
three categories: low risk, unclear risk or high risk of bias. 
Data was entered into Review Manager, V.5.3.30
search strategy
We searched CENTRAL, MEDLINE, Embase, CINAHL, 
PsycINFO,  ClinicalTrials. gov, iCTRP and ISI CPCI up to 
March 2015. For CENTRAL, MEDLINE, Embase and 
PsycINFO, two different search strategies were used: one 
for efficacy and one for adverse events. To overcome the 
risk of poor indexing and abstracting, individual brand 
names were listed within the search strategies. We also 
contacted experts in the field and pharmaceutical compa-
nies for published and unpublished data, and we checked 
review articles for additional relevant studies. Relevant 
articles in non-English languages were translated. Further 
details on the data sources and search criteria are avail-
able in the Cochrane systematic review.5
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Outcomes and comparisons
The primary outcomes were ADHD symptoms (ie, 
teacher, parent and observer-rated) and serious adverse 
events. We chose the teacher ratings as our primary 
outcome since ADHD symptoms are more readily detect-
able in the school setting.31 The secondary outcomes were 
non-serious adverse events.5 We first compared the end 
of parallel trials to the end of first-period of crossover 
trials. If no significant differences were found, we pooled 
the first-period of crossover trials with the parallel trials 
and compared these data to the end-period of the cross-
over trials. First- period and end-period crossover trials 
were compared to assess the risk of carryover and period 
effects.
statistical analyses
We summarised dichotomous data as risk ratios (RR) with 
95% CI, and if trials used the same continuous outcome, 
we summarised the data as mean group differences with 
95% CI. For different continuous outcome measures, 
we used standardised mean differences with 95% CI. We 
applied both fixed effects and random effects models. If 
we were not able to retrieve the end of the first-period 
crossover data, we created groups of crossover trials 
with the end of the last-period data only. We originally 
intended to adjust for unit-of-analysis errors in crossover 
trials by conducting a covariate analysis for the contin-
uous data, but the data were insufficient for this. For 
the dichotomous data, we were unable to adjust for the 
variance to account for the correlation coefficient due to 
insufficient data. We could not estimate the RR using the 
marginal probabilities and we therefore used the end of 
the last-period data for calculating the RR.32
We presented the results in forest plots, and χ² and 
I² were applied to test for statistical heterogeneity. χ² 
assesses whether observed differences in the results are 
compatible with chance alone. χ² may have low power in 
meta-analyses of a few studies or small sample sizes and 
should therefore be interpreted with caution. I² describes 
the percentage of variability in the results that is caused 
by heterogeneity rather than sampling error (chance). 
Roughly speaking, I2 <40% might not be important, 
30%–60% might represent moderate heterogeneity, 
50%–90% might represent substantial heterogeneity and 
75%–100%, considerable heterogeneity.23
results
The search up to March 2015 identified 14 431 initial 
records. After removal of duplicates and irrelevant arti-
cles by abstract screening, 1460 publications were assessed 
for full-text inclusion. Subsequently, 185 randomised 
trials from 449 reports were included, of which 38 were 
parallel trials (n=5111 participants) and 147 were cross-
over trials (n=7134 participants) (figure 1). Only five 
of our crossover trials provided data from the different 
periods of the trial, either described in the publication 
or acquired after our requests to the authors.21 33–36  One 
trial had insufficient data for use in the meta-analyses. 
Lehmkuhl36 was part of a larger study,37 and data were 
acquired directly from HB Pharma (part of Medici). Of 
the five eligible trials, only two had data on teacher-rated 
ADHD symptoms.34 35
Characteristics of included studies
We assessed 179 (97%) trials at high risk of bias and six 
(3%) at low risk of bias.5 However, these six could poten-
tially have suffered from lack of blinding because of the 
common, easily recognisable adverse effects of methyl-
phenidate.5 Most trials were from high-income countries, 
the boy to girl ratio was 5:1 and participant ages ranged 
from 3 to 21 years with an average of 9.7 years. The average 
trial duration was less than 2 months, with only four trials 
lasting longer than 6 months. The median duration of the 
38 parallel-group trials was 49 days (range 1 to 425 days, 
mean 75) and for the 147 crossover trials it was a total 14 
days (1 to 56 days, mean 16 days).
ADhD symptoms
Parallel trials compared with first-period crossover trials
The analysis on teacher-rated ADHD symptoms included 
only 19 trials (n=1601) (figure 2). No significant differ-
ences were found between the end of the parallel trials 
and the end of the first-period of crossover trials (χ²=1.06, 
df=1, p=0.30, I²=5.5%). Moreover, no differences were 
found for independent assessor-rated ADHD symptoms 
(χ²=0.30, df=1,(p=0.58, I²=0%) or parent-rated ADHD 
symptoms (χ²=0.00, df=1,p=0.96, I²=0%) in these two 
groups of trials.
Parallel trials plus first-period crossover trials compared with end-
period crossover trials
The analysis of teacher-rated ADHD symptoms included 
75 trials (n=6247) (figure 3). No significant differences 
were found between the end of the parallel group trials 
plus the end of the first period of the crossover trials and 
end of the last period of the crossover trials (Χ²=3.25, 
df=1, p=0.07, I²=69.2%). Also, no differences were found 
for parent ratings (Χ²=1.58, df=1, p=0.21, I²=36.6%) 
in these two groups of trials. However, these groups of 
trials differed regarding observer ratings (χ²=4.23, df=1, 
p=0.04, I²=76.4), with methylphenidate exerting larger 
effects in the end of the last period of the crossover trials.
First-period compared with end-period crossover trials
The analysis of teacher-rated ADHD symptoms included 
only two trials (n=95 participants) (figure 4). The effect 
estimates as well as the 95% CI are comparable and do 
not indicate any difference between subgroups. There 
were insufficient data on parent ratings and indepen-
dent-assessor ratings to conduct independent analyses.
serious adverse events
Parallel trials compared with end-period crossover trials
One analysis compared the end of the parallel-group to 
the end of the last period of the crossover trials on serious 
adverse events (figure 5). The analysis with 17 trials found 
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart. ADHD, attention deficit hyperactivity 
disorder; RCT, randomised clinical trials.
Protected by copyright.
 o
n
 O
ctober 24, 2019 at Kobenhavns Universitets Bibliotek.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026478 on 30 March 2019. Downloaded from 
5Krogh HB, et al. BMJ Open 2019;9:e026478. doi:10.1136/bmjopen-2018-026478
Open access
no significant differences between the two groups of trials 
(Χ²=0.31, df=1, p=0.58, I²=0%).
non-serious adverse events
Parallel trials compared with the first-period crossover trials
One analysis compared parallel-group trials to first-period 
crossover trials. The analysis included 20 parallel-group 
trials and one crossover trial with data from first period 
(online supplementary file 1). No significant differences 
were found between the two groups of trials (χ²=1.45, 
df=1, p=0.23, I²=31.1%).
Parallel plus first-period crossover trials compared with end-period 
crossover trials
One analysis compared parallel-group plus end of first-pe-
riod crossover trials to the end of last period of crossover 
trials for non-serious adverse events (online supplemen-
tary file 2). The analysis with data from 42 trials found no 
significant differences between the two groups of trials 
(χ²=0.06, df=1, p=0.80, I²=0%).
First-period compared with end-period crossover trials
One analysis compared end of first-period crossover 
trials to end of last period crossover trials – one study was 
included (online supplementary file 3). The effect esti-
mates as well as the 95% are comparable and do not indi-
cate any difference between subgroups.
subgroup analysis
We conducted a subgroup analysis investigating the 
impact of bias. We found that the intervention effect did 
not vary according to risk of bias (test for subgroup differ-
ences: χ²=2.43, df=1, p=0.12, I²=58.9%). However, it is 
likely that the trials initially judged to be at low risk of bias 
are in fact trials at high risk of bias because methylpheni-
date gives rise to various prevalent and easily recognisable 
adverse events, leading to potential loss of blinding and 
biased symptom ratings. This may result in overestima-
tions of benefits and underestimations of harms.38–40
In the original review,5 we conducted several subgroup 
analyses, for example, types of scales, duration of treat-
ment and medication status. These were not deemed rele-
vant for this publication. For more information on these, 
we refer to the original review.
DIsCussIOn
We aimed to investigate the methodological advantages 
and disadvantages of parallel and crossover designs of 
RCTs on methylphenidate for children and adolescents 
with ADHD. The study is important because RCTs with 
children and adolescents are challenging to conduct and 
often raise ethical concerns. Moreover, both parallel and 
crossover designs are used to investigate methylphenidate 
Figure 2 Data from the end of the parallel trials compared with the end of the first period of the crossover trials on the 
effects of methylphenidate compared with placebo or no intervention on teacher-rated attention deficit hyperactivity disorder 
symptoms.
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Figure 3 Data from the end of the parallel trials plus the end of the first period of the crossover trials compared with data from 
the end of the last period of the crossover trials on the effects of methylphenidate versus placebo or no intervention on teacher-
rated attention deficit hyperactivity disorder symptoms.
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for children and adolescents, without anyone, to our 
knowledge, having investigated specifically whether both 
types of designs are suitable. table 1 summarises poten-
tial advantages and disadvantages of parallel and cross-
over designs based on the findings from this study and 
previous literature.
For teacher-rated ADHD symptoms, we found no signif-
icant differences when comparing the end of the first 
period of the crossover trials to that of the parallel trials, 
the end of the first period to the end of the last period of 
crossover trials, or when comparing the end of the first 
period of the crossover trials plus that of the parallel group 
Figure 4 Data from the end of the first period compared with data from the end of the last period of crossover trials on the 
effects of methylphenidate versus placebo or no intervention on teacher-rated attention deficit hyperactivity disorder symptoms.
Figure 5 Data from parallel trials compared with data from end of the last period of crossover trials on serious adverse events.
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trials to the end of the last period of the crossover trials. 
We also found no significant differences when looking 
at parent ratings for the abovementioned analyses. 
However, we found significant differences in the observ-
er-rated end-of- first -period crossover trials compared 
with parallel trials, with methylphenidate exerting larger 
effects in the end of the last -period of crossover trials.
Regarding our analyses on serious adverse events, we 
found no significant differences when comparing parallel 
trials with the last period of crossover trials, and no indi-
cations of period and carryover effects were found.
Only 10 out of the 147 included crossover trials (7%) 
addressed or mentioned the issue of carryover effects, 
which is fewer than previous studies have reported.6 17 
We found no risk of carryover and period effects when 
comparing the end of the first period to that of the last 
period of crossover trials (figure 4), but this analysis was 
based on two trials only. When comparing the end of 
the parallel trials plus the end of the first period of cross-
over trials to the end of the last period of crossover trials 
for ADHD symptoms, we found no significant subgroup 
differences either (figure 3) which further decreases the 
likelihood of carryover and period effects in the cross-
over trials. Notably, this analysis had heterogeneity of 
I2=69.2%, indicating substantial heterogeneity between 
the groups of trials.
When meta-analyses incorporate crossover data, 
the unit of analysis errors may bias the results.15 The 
insignificant subgroup differences between the end of 
the parallel trials and the last period of the crossover trials 
suggest, however, that such errors were not major. The 
majority of the crossover trials presented only end-of-last 
period data, which undermines their interpretability and 
generalisability. This also underlines a larger problem 
with incorporating crossover trials in meta-analyses: data 
on within-individual comparison of treatments from 
paired analyses and data from multiple time periods are 
often unavailable to review authors.13 We only received 
few positive responses when asking for missing data.
A washout period between interventions is recom-
mended when using crossover designs to reduce period 
and carryover effects.9 However, only 27 out of the 147 
crossover trials (19%) included a washout period, lasting 
between 1 to 14 days. In total, 79 (56%) of the cross-
over trials did not include a washout period, and in the 
remaining 41 (29%), it was unclear whether washout 
periods were used. Of the trials with a washout period, 
only 15 (10%) provided arguments for its necessity. 
However, the results from this study indicate that the lack 
of reporting may have contributed to less bias than one 
might expect, possibly because of the short half-life and 
brief effects of methylphenidate.
strengths and limitations
This study has several strengths. A protocol was 
published following The Cochrane Collaboration guide-
lines,23 a broad and comprehensive literature search 
was conducted, and we included both published and 
Table 1 Methodological advantages and disadvantages with crossover and parallel randomised designs when investigating 
methylphenidate for children and adolescents with attention deficit hyperactivity disorder. Based on previous literature and the 
present findings
Advantages Disadvantages
Crossover 
designs
Suitable for stable conditions, when interventions 
are short-lived and do not cure the condition (eg, 
methylphenidate for ADHD.
Crossover trials did not alter effect estimates relative 
to parallel trials in the present study with the exception 
of one observer-rated analysis of ADHD symptoms. 
Commonly reported biases with crossover studies, such 
as period and carryover effects, were not documented.
Crossover trials need fewer participants than parallel 
trials to achieve sufficient power, which may decrease 
the use of participant and resource consumption.
This study did not document any unit of analysis errors 
from using end-of-trial data from crossover trials in 
meta-analyses even after ignoring the within-patient 
correlations.
The present study was constrained by low evidence 
quality. Therefore, one cannot state for certain whether 
crossover trials on methylphenidate for ADHD are free of 
methodological biases relative to parallel trials.
Crossover trials often last longer than parallel trials, 
which may increase overall attrition rates.
Data from all time periods in crossover trials are 
often unavailable, and because participants switch 
interventions, causality of adverse events and effects 
may be difficult to determine in some circumstances.
There may be undocumented adverse events 
associated with exposing participants to multiple 
interventions in a trial.
Parallel 
designs
Parallel trials are versatile, simple and easy to 
incorporate into meta-analyses when compared with 
crossover trials.
By including more participants, parallel trials will have 
higher external validity regarding benefits and harms 
compared with crossover trials.
Researchers do not need to address issues concerning 
unit of analysis errors, period effects and carryover 
effects or washout periods between interventions.
Parallel designs usually require larger sample sizes than 
crossover studies, which may increase financial costs.
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unpublished data. Review authors worked independently 
in pairs of two, and all data from both parallel and cross-
over trials were analysed in accordance with the Cochrane 
Handbook.23 Furthermore, several of the analyses that 
compared parallel trials to crossover trials included over 
1000 participants, which may have increased statistical 
power and decreased the risk of type II errors.
Some limitations should also be highlighted. First, the 
Food and Drug Administration and European Medicine 
Agency databases were not searched for unpublished 
data. Second, the analysis comparing first-period and 
last-period crossover trials included two trials only.
The best way to analyse intervention effects in crossover 
trials is to conduct paired analyses, and the best way to 
investigate the carryover effect and period effect is to look 
at the within-trial data. Unfortunately, the reporting of 
crossover trials were very variable, and the data required 
to include paired analysis in meta-analysis were not avail-
able to us. We believe that both period effect and carry-
over effect, as well as unit of analysis error (error due to 
using end of period data as these were independent data) 
would have affected the estimates and showed signifi-
cant group differences between the parallel group and 
the crossover trials investigating the same interventions 
for children and adolescents with ADHD. When we, in 
our first analysis, compared the end of the parallel group 
trials and the end of the first period of crossover trials 
with the end of the last period of crossover trials (using 
end-of-period data as if these were independent data 
which they, of course, are not) one would expect signifi-
cant subgroup differences between the groups due to unit 
of analysis error (error due to using end of period data as 
if these were independent data) as well as due to carryover 
effect. When we, in one of the other analysis, compared 
end-of-first period crossover trials with the end-of-the-last-
period crossover trials, one would also expect differences 
had there been any carryover effect from the methylphe-
nidate treatment during the first period to the placebo 
treatment during the second period affecting the effect 
of the placebo treatment.
We also carried out a search for additional articles 
comparing the use of the two designs, but no articles 
describing methylphenidate or similar drugs were found. 
Other areas where the choice of design has been discussed 
include antiepileptic drugs, sleep research and infertility 
trials.7 8 41
COnClusIOns
This study mostly found no signs of period effects or carry-
over effects in crossover trials assessing methylphenidate 
for children and adolescents with ADHD. Accordingly, 
crossover trials and parallel trials on methylphenidate for 
children and adolescents with ADHD seem to offer the 
same advantages and pose similar problems as described 
for these two designs in other therapeutic areas. Despite 
the insignificant results, crossover trial suitability for 
methylphenidate trials should still be questioned. It can 
be harder to detect and analyse adverse events in cross-
over trials, especially the late onset adverse events, since 
the treatment periods are often short. The two types of 
designs also have clear methodological and practical 
differences concerning what statistical analyses to use, 
systematic bias, ethical concerns about exposing children 
or adolescents to multiple interventions, and financial 
costs.17 42 Authors of crossover trials ought to report more 
comprehensively the data for end of all trial periods. 
Review authors should know how to incorporate the 
widely used crossover design into meta-analyses, in order 
not to lose valuable data.
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